Oncolytics Biotech (ONCY) Misses Q3 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500, Nasdaq rise as tech stocks gain ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts ONCY Hot Sheet
Join SI Premium – FREE
Oncolytics Biotech (NASDAQ: ONCY) reported Q3 EPS of ($0.12), $0.02 worse than the analyst estimate of ($0.10).
For earnings history and earnings-related data on Oncolytics Biotech (ONCY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Expedia (EXPE) PT Raised to $204 at Stifel
- Novo Nordisk (NVO) call put ratio 2.8 calls to 1 put with a focus on November 6 weekly calls into quarter results
- Centurion Minerals to resume trading, pursues Suriname gold project
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
